pSivida (PSDV) Says Second Phase 3 Study for Durasert Three-year Treatment for Posterior Segment Uveitis Maintains Positive Efficacy, Safety Profile at 12 Months
Tweet Send to a Friend
pSivida Corp. (NASDAQ: PSDV) today announced that results from the Company's second Phase 3 trial for Durasert three-year treatment ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
